And our current thinking about obesity, and one of the components of the disease of obesity, is that some individuals although they all have GLP-1 and these other gut hormones, amylin, glucagon, GIP, that's what they're called that signal, for some reason, is not getting to the brain in ample amounts to tell the individual to feel full, satiated, and stop eating
Also, SSRIs and SNRIs show these effects in association with an antidepressant action
The results of the phase 1 studies of AMG133 could provide insights into the role of GIP receptor antagonism within glucose metabolism, however, determining the exact effect of the GIP receptor antagonism remains challenging due to an anticipated influence of GLP-1 receptor agonism
Hype Scientific evidence for intravenous glutathione is limited and mixed